The stock of Karyopharm Therapeutics Inc (KPTI) has seen a -1.94% decrease in the past week, with a -16.11% drop in the past month, and a -27.25% decrease in the past quarter. The volatility ratio for the week is 5.48%, and the volatility levels for the past 30 days are at 8.02% for KPTI. The simple moving average for the last 20 days is -8.86% for KPTI’s stock, with a simple moving average of -19.47% for the last 200 days.
Is It Worth Investing in Karyopharm Therapeutics Inc (NASDAQ: KPTI) Right Now?
Company’s 36-month beta value is 0.23.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KPTI is 114.24M, and currently, short sellers hold a 16.08% ratio of that floaft. The average trading volume of KPTI on August 15, 2024 was 1.30M shares.
KPTI) stock’s latest price update
Karyopharm Therapeutics Inc (NASDAQ: KPTI)’s stock price has gone rise by 1.75 in comparison to its previous close of 0.81, however, the company has experienced a -1.94% decrease in its stock price over the last five trading days. zacks.com reported 2024-08-06 that Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago.
Analysts’ Opinion of KPTI
Many brokerage firms have already submitted their reports for KPTI stocks, with Piper Sandler repeating the rating for KPTI by listing it as a “Overweight.” The predicted price for KPTI in the upcoming period, according to Piper Sandler is $8 based on the research report published on January 19, 2023 of the previous year 2023.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see KPTI reach a price target of $10, previously predicting the price at $7. The rating they have provided for KPTI stocks is “Outperform” according to the report published on November 04th, 2022.
JP Morgan gave a rating of “Neutral” to KPTI, setting the target price at $8 in the report published on February 09th of the previous year.
KPTI Trading at -11.31% from the 50-Day Moving Average
After a stumble in the market that brought KPTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.84% of loss for the given period.
Volatility was left at 8.02%, however, over the last 30 days, the volatility rate increased by 5.48%, as shares sank -9.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.05% lower at present.
During the last 5 trading sessions, KPTI fell by -0.55%, which changed the moving average for the period of 200-days by +1.15% in comparison to the 20-day moving average, which settled at $0.8978. In addition, Karyopharm Therapeutics Inc saw -4.96% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KPTI starting from Paulson Richard A., who sale 3,608 shares at the price of $0.93 back on Aug 06 ’24. After this action, Paulson Richard A. now owns 1,142,881 shares of Karyopharm Therapeutics Inc, valued at $3,355 using the latest closing price.
Poulton Stuart, the EVP, Chief Development Officer of Karyopharm Therapeutics Inc, sale 2,883 shares at $1.06 during a trade that took place back on Jul 30 ’24, which means that Poulton Stuart is holding 326,628 shares at $3,056 based on the most recent closing price.
Stock Fundamentals for KPTI
Current profitability levels for the company are sitting at:
- -0.9 for the present operating margin
- 0.96 for the gross margin
The net margin for Karyopharm Therapeutics Inc stands at -0.62. The total capital return value is set at -0.84.
Based on Karyopharm Therapeutics Inc (KPTI), the company’s capital structure generated 3.11 points at debt to capital in total, while cash flow to debt ratio is standing at -0.67. The debt to equity ratio resting at -1.47. The interest coverage ratio of the stock is -14.21.
Currently, EBITDA for the company is -129.01 million with net debt to EBITDA at -0.87. When we switch over and look at the enterprise to sales, we see a ratio of 1.47. The receivables turnover for the company is 3.83for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.
Conclusion
In a nutshell, Karyopharm Therapeutics Inc (KPTI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
